Neuroprotection after cardiac arrest with 2-iminobiotin: a single center phase IIa study on safety, tolerability, and pharmacokinetics

BACKGROUND: Brain injury is a serious problem in patients who survive out-of-hospital cardiac arrest (OHCA). Neuroprotective drugs could reduce hypoxic–ischemic reperfusion injury. The aim of this study was to investigate the safety, tolerability, and pharmacokinetics (PK) of 2-iminobiotin (2-IB), a...

Descripción completa

Detalles Bibliográficos
Autores principales: Admiraal, M. M., Velseboer, D. C., Tjabbes, H., Vis, P., Peeters-Scholte, C., Horn, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272808/
https://www.ncbi.nlm.nih.gov/pubmed/37332991
http://dx.doi.org/10.3389/fneur.2023.1136046

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272808/
https://www.ncbi.nlm.nih.gov/pubmed/37332991
http://dx.doi.org/10.3389/fneur.2023.1136046

Ejemplares similares